The latest biotech news

News and Trends 20 Oct 2022

VectorBuilder raises funds for gene delivery R&D

VectorBuilder Biotechnology (Guangzhou) Co., Ltd., a gene delivery enterprise, has completed a series C round with CNY410 million ($56.7 million). The funding was co-led by Legend Capital. The proceeds will help VectorBuilder promote the upgrading and capacity expansion of its gene delivery R&D and production technology platform, further accelerate its global business presence, and boost […]

October 20, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 20 Oct 2022

License from Helmholtz Munich will enable progression of brain cancer treatment

A treatment for one of the most aggressive and difficult to treat cancers is the focus of a licensing option that has been executed by Isotope Technologies Munich SE (ITM). The license from Helmholtz Munich was announced yesterday (October 19). The targeted radionuclide therapy with ITM-31 targets a specific protein (antigen) called CA XII, which […]

October 20, 2022 - 3 minutesmins - By Liza Laws

News and Trends 19 Oct 2022

Multi-year agreement to boost women’s reproductive health

A multi-year agreement between BioSkryb Genomics and Cooper Genomics, a reproductive health company was announced yesterday (October 18). The agreement is to license BioSkyrb’s proprietary genomic amplification technology. Cooper will utilize the Bioskryb technology to enhance their preimplantation genetic testing (PGT) capabilities. The agreement will also allow Cooper to boost BioSkyrb’s tech for the PGT […]

October 19, 2022 - 3 minutesmins - By Liza Laws

News and Trends 19 Oct 2022

Immunethep receives European Innovation Council funding for clinical trials

Immunethep, a Portuguese biotech startup, has been selected by the European Innovation Council (EIC) to receive funding from its EIC Accelerator program. Immunethep will receive initially a €2.5 million ($2.5 million) grant and is eligible for additional equity investment from the EIC Fund for a project with a total investment of €17.5 million ($17.1 million). […]

October 19, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 19 Oct 2022

CDF15 cytokine a promising therapeutic target against type 2 diabetes

CDF15 cytokine a promising therapeutic target against type 2 diabetes Researchers have conducted a review study on growth differentiation factor 15 (GDF15) — a protein expressed under physiological stress conditions — and its potential impact on the treatment for type 2 diabetes. It was led by Professor Manuel Vázquez-Carrera, from the Faculty of Pharmacy and […]

October 19, 2022 - 5 minutesmins - By Jim Cornall

HealthTech Innovation Days HTID Paris 2022

News and Trends 19 Oct 2022

HealthTech Innovation Days brings European healthtech ecosystem together

The 4th edition of HealthTech Innovation Days (HTID), organized by HealthTech For Care, took place recently in Paris, France. The two-day event had the objective of finding financing and encouraging new industrial partnerships to accelerate the development and market access of new products and treatments for all patients. Around 1,600 formal and informal face-to-face and […]

October 19, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 19 Oct 2022

Aqemia raises €30M for AI-enabled drug discovery pipeline

Aqemia has raised €30 million ($29.5 million) in a series A funding round to scale up drug discovery, through a first-in-class technological platform combining quantum-inspired physics and machine learning. The funding was led by Eurazeo and Bpifrance through its Large Venture fund, with the participation of previous investor Elaia. In three years, Aqemia has grown […]

October 19, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 19 Oct 2022

Report says 20% of global cancer deaths could be avoided

A new study by members of the Bloomberg New Economy International Cancer Coalition says at least 1.5 million deaths from cancer could be avoided each year. This is 20% of the annual global deaths resulting from cancer. The study says this could happen if international regulations around patient trials were more standardized and people placed […]

October 19, 2022 - 6 minutesmins - By Jim Cornall

News and Trends 19 Oct 2022

Domain Therapeutics to start clinical trials of solid tumor treatment

Domain Therapeutics says its immuno-oncology candidate has been cleared in Belgium and France, leading to a phase I clinical trial. It has cleared its clinical trial applications with the ANSM (Agence Nationale de Sécurité du Médicament et des produits de santé) in France and the AFMPS (Agence Fédérale des Médicaments et des Produits de Santé) […]

October 19, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 19 Oct 2022

Nucleome Therapeutics raises £37.5M to deliver precision medicines

U.K. biotech company Nucleome Therapeutics Limited has closed an oversubscribed £37.5 million ($42.4 million) series A financing round. The funds will be used to advance the company’s autoimmune disease programs, fuel expansion of its dark genome atlas and further develop its pioneering platform. The financing was led by new investor M Ventures, the strategic, corporate […]

October 19, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 18 Oct 2022

Empyrean Neuroscience launches with $22M to target CNS disorders

Empyrean Neuroscience, Inc. has launched with $22 million in series A financing and a genetic engineering platform to advance a pipeline of neuroactive compounds targeting disorders of the central nervous system (CNS). The company, based in New York City and Cambridge, U.K., is founded on a proprietary platform designed to genetically engineer small molecule therapeutics […]

October 18, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 18 Oct 2022

EditForce creates U-to-C RNA-editing technology

EditForce, Inc., headquartered in Fukuoka, Japan, has created the world’s first RNA-editing technology that enables RNA-editing bases to be changed from U (uracil) to C (cytosine). The RNA editing company also demonstrated that technology works in human cells in a joint study with Takahiro Nakamura, Faculty of Agriculture, Kyushu University. The researchers said the study […]

October 18, 2022 - 2 minutesmins - By Jim Cornall

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

VectorBuilder raises funds for gene delivery R&D

License from Helmholtz Munich will enable progression of brain cancer treatment

Multi-year agreement to boost women’s reproductive health

Immunethep receives European Innovation Council funding for clinical trials

CDF15 cytokine a promising therapeutic target against type 2 diabetes

HealthTech Innovation Days brings European healthtech ecosystem together

Aqemia raises €30M for AI-enabled drug discovery pipeline

Report says 20% of global cancer deaths could be avoided

Domain Therapeutics to start clinical trials of solid tumor treatment

Nucleome Therapeutics raises £37.5M to deliver precision medicines

Empyrean Neuroscience launches with $22M to target CNS disorders

EditForce creates U-to-C RNA-editing technology

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!